{"id":2900,"date":"2024-02-28T13:32:10","date_gmt":"2024-02-28T10:32:10","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=2900"},"modified":"2024-02-29T09:05:09","modified_gmt":"2024-02-29T06:05:09","slug":"boehringer-ingelheim-turkiye-genel-muduru-okan-guner-nadir-hastaliklara-sahip-bireylere-yalniz-degilsiniz-diyoruz","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=2900","title":{"rendered":"Boehringer Ingelheim T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Okan G\u00fcner: \u201cNadir Hastal\u0131klara Sahip Bireylere \u2018Yaln\u0131z De\u011filsiniz\u2019 Diyoruz\u201d"},"content":{"rendered":"\n

Bug\u00fcn ve nesiller boyunca insanlar\u0131n ve hayvanlar\u0131n sa\u011fl\u0131\u011f\u0131n\u0131, ya\u015famlar\u0131n\u0131 iyile\u015ftirecek, d\u00f6n\u00fc\u015ft\u00fcrecek \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 tedaviler geli\u015ftirme misyonuyla \u00e7al\u0131\u015ft\u0131klar\u0131n\u0131 vurgulayan <\/strong>Boehringer Ingelheim T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Okan G\u00fcner, \u015firketin nadir hastal\u0131klar alan\u0131ndaki yakla\u015f\u0131m\u0131n\u0131 ve Ar-Ge \u00e7al\u0131\u015fmalar\u0131n\u0131 aktard\u0131.   <\/strong><\/strong><\/p>\n\n\n\n

Nadir hastal\u0131klar ile ilgili bilgi verir misiniz?<\/strong><\/p>\n\n\n\n

Nadir g\u00f6r\u00fclen hastal\u0131klar, nadir olarak tan\u0131mlanmakla birlikte asl\u0131nda d\u00fcnya n\u00fcfusunun \u00f6nemli bir kesimini etkiliyor. Bug\u00fcn, d\u00fcnya \u00e7ap\u0131nda t\u00fcm hastal\u0131klar\u0131n 8 binini nadir hastal\u0131klar olu\u015fturuyor. 300 milyon insan nadir hastal\u0131klarla ya\u015f\u0131yor <\/sup>ve t\u0131bbi ihtiya\u00e7lar\u0131n\u0131 kar\u015f\u0131layacak tedavileri bekliyor. Nadir hastal\u0131klar, toplumda 2000\u2019de birden az s\u0131kl\u0131kla g\u00f6r\u00fclen hastal\u0131klar\u0131 ifade ediyor. S\u0131kl\u0131\u011f\u0131 az olmas\u0131na ra\u011fmen \u00fclkemizde yakla\u015f\u0131k 5 milyon ki\u015finin bu hastal\u0131klardan etkilendi\u011fi tahmin ediliyor ve toplumun y\u00fczde 5-8\u2019inin nadir hastal\u0131klardan birine sahip oldu\u011fu biliniyor.<\/p>\n\n\n\n

G\u00fcn\u00fcm\u00fczde, genellikle genetik k\u00f6kenli olan nadir hastal\u0131klar\u0131n y\u00fczde 70’i \u00e7ocuklar\u0131 etkiliyor. Hem genetik k\u00f6kenli olmalar\u0131 hem de tan\u0131lar\u0131n\u0131n zor olmas\u0131, tedavi se\u00e7eneklerinin ve tedaviye eri\u015fimin k\u0131s\u0131tl\u0131 olmas\u0131 gibi nedenlerle bu hastal\u0131klar maalesef y\u00fcksek oranda \u00f6l\u00fcm ve sakatl\u0131kla sonlan\u0131yor.<\/p>\n\n\n\n

Hangi nadir hastal\u0131klara y\u00f6nelik tedavi \u00e7\u00f6z\u00fcmleri sunuyorsunuz?<\/strong><\/p>\n\n\n\n

Nadir hastal\u0131klar alan\u0131nda a\u011f\u0131rl\u0131kl\u0131 olarak; akci\u011ferlerde skar dokular\u0131n olu\u015fmas\u0131na yol a\u00e7an \u0130diopatik Pulmoner Fibrozis (\u0130PF), v\u00fccut dokular\u0131 ile cildin tepkimeye ge\u00e7mesine, sertle\u015fmesine neden olan Sistemik Skleroz (Skleroderma), nadir cilt bozukluklar\u0131 ve kanser gibi hastal\u0131klara y\u00f6nelik tedaviler sunuyoruz. Boehringer Ingelheim olarak bug\u00fcne kadar tatmin edici bir \u015fekilde tedavi edilemeyen hastal\u0131klara \u00f6nemli katk\u0131lar sa\u011flama hedefiyle ya\u015famlar\u0131 iyile\u015ftirecek ve d\u00f6n\u00fc\u015ft\u00fcrecek \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 tedaviler geli\u015ftirmeye devam edece\u011fiz.   <\/p>\n\n\n\n

Nadir hastal\u0131klar alan\u0131nda hangi \u00e7al\u0131\u015fmalar\u0131 ger\u00e7ekle\u015ftiriyorsunuz?<\/strong><\/p>\n\n\n\n

Boehringer Ingelheim olarak, bug\u00fcn ve nesiller boyunca insanlar\u0131n ve hayvanlar\u0131n sa\u011fl\u0131\u011f\u0131n\u0131, ya\u015famlar\u0131n\u0131 iyile\u015ftirecek, d\u00f6n\u00fc\u015ft\u00fcrecek \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 tedaviler geli\u015ftirme misyonuyla \u00e7al\u0131\u015f\u0131yoruz. Bu misyonumuz do\u011frultusunda, yenilik\u00e7i ila\u00e7lar\u0131m\u0131zla hen\u00fcz kar\u015f\u0131lanamayan tedavi ihtiya\u00e7lar\u0131na cevap vermeyi hedefliyoruz. D\u00fcnyadaki en b\u00fcy\u00fck hasta topluluklar\u0131ndan birini temsil eden nadir hastal\u0131klara sahip bireylere Boehringer Ingelheim olarak yaln\u0131z de\u011filsiniz diyoruz. Bu ama\u00e7la, daha fazla hastan\u0131n hayat\u0131na dokunmak ve hastalar\u0131n do\u011fru zamanda do\u011fru tedavi ile bulu\u015fmas\u0131n\u0131 sa\u011flamak ad\u0131na Ar-Ge \u00e7al\u0131\u015fmalar\u0131m\u0131z\u0131n yan\u0131 s\u0131ra, hasta dernekleri, ara\u015ft\u0131rmac\u0131lar, yeni giri\u015fimler ve sa\u011fl\u0131k yetkilileri ve kurumlar\u0131yla i\u015f birliklerini oda\u011f\u0131m\u0131za al\u0131yoruz. <\/p>\n\n\n\n

Nadir hastal\u0131klarla m\u00fccadele eden hastalar\u0131n pek \u00e7ok a\u00e7\u0131dan zorlu bir s\u00fcre\u00e7ten ge\u00e7tiklerini biliyoruz. Bu nedenle, hastalar\u0131 daha fazla sa\u011fl\u0131kla bulu\u015fturmak i\u00e7in onlar\u0131 dinlemenin \u00f6nemine inan\u0131yor, onlarla aktif olarak etkile\u015fime ge\u00e7iyoruz. Biliyoruz ki, hastalar\u0131m\u0131z bizim do\u011fru yolda ilerlememiz i\u00e7in en \u00f6nemli k\u0131lavuzumuz.<\/p>\n\n\n\n

Bu alandaki Ar-Ge \u00e7al\u0131\u015fmalar\u0131n\u0131zdan bahseder misiniz?<\/strong><\/p>\n\n\n\n

\u00dclkemizde, nadir kanserler de dahil olmak \u00fczere nadir hastal\u0131klar, t\u00fcm aktif klinik ara\u015ft\u0131rmalar\u0131n y\u00fczde 63’\u00fcn\u00fc olu\u015fturuyor. <\/sup>Boehringer Ingelheim olarak, her hastan\u0131n ve hastal\u0131\u011f\u0131n benzersiz oldu\u011fu ger\u00e7e\u011finden yola \u00e7\u0131k\u0131yor, nadir olarak tan\u0131mlanan hastal\u0131klara y\u00f6nelik, alan\u0131nda ilk olan tedaviler geli\u015ftirmeyi ama\u00e7l\u0131yoruz. Bununla birlikte, ara\u015ft\u0131rma ve geli\u015ftirme programlar\u0131m\u0131z ile kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131n y\u00fcksek oldu\u011fu hastal\u0131klara y\u00f6nelik \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerin bir sonraki faz\u0131na da odaklan\u0131yoruz. Bu ama\u00e7la, ara\u015ft\u0131rma ve geli\u015ftirme yat\u0131r\u0131mlar\u0131m\u0131z\u0131 s\u00fcrd\u00fcr\u00fclebilir olarak art\u0131r\u0131yoruz. Nadir hastal\u0131klar\u0131 da i\u00e7erecek \u015fekilde 2022 y\u0131l\u0131nda insan sa\u011fl\u0131\u011f\u0131na y\u00f6nelik Ar-Ge harcamalar\u0131m\u0131z bu alanda \u00fcretilen global \u00e7aptaki net ciromuzun y\u00fczde 24,9’una denk geliyor. Yine <\/a>2022 y\u0131l\u0131nda yeni \u00fcretim tesislerine ve donan\u0131mlara yap\u0131lan yat\u0131r\u0131mlar\u0131m\u0131z da 1 milyar Euroyu a\u015ft\u0131.<\/p>\n\n\n\n

MPR -TR -100869<\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Bug\u00fcn ve nesiller boyunca insanlar\u0131n ve hayvanlar\u0131n sa\u011fl\u0131\u011f\u0131n\u0131, ya\u015famlar\u0131n\u0131 iyile\u015ftirecek, d\u00f6n\u00fc\u015ft\u00fcrecek \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 tedaviler geli\u015ftirme misyonuyla \u00e7al\u0131\u015ft\u0131klar\u0131n\u0131 vurgulayan Boehringer Ingelheim T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Okan G\u00fcner, \u015firketin nadir hastal\u0131klar alan\u0131ndaki yakla\u015f\u0131m\u0131n\u0131 ve Ar-Ge \u00e7al\u0131\u015fmalar\u0131n\u0131 aktard\u0131.    Nadir hastal\u0131klar ile ilgili bilgi verir misiniz? Nadir g\u00f6r\u00fclen hastal\u0131klar, nadir olarak tan\u0131mlanmakla birlikte asl\u0131nda d\u00fcnya n\u00fcfusunun \u00f6nemli bir kesimini …<\/p>\n","protected":false},"author":1,"featured_media":2902,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2900"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2900"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2900\/revisions"}],"predecessor-version":[{"id":2903,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2900\/revisions\/2903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/2902"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}